Skip to main content
Full access
Letter to the Editor
Published Online: 1 July 1998

Hypersalivation Coincident With Olanzapine Treatment

Publication: American Journal of Psychiatry
TO THE EDITOR: Drooling, often manifested as pillow wetting during sleep, is a common adverse effect of the atypical antipsychotic clozapine (1). In light of clozapine's propensity to cause anticholinergic effects, it is surprising that patients complain of drooling rather than of dry mouth—the expected salivary anticholinergic response.
Olanzapine, a derivative of clozapine, is an atypical antipsychotic with a receptor-binding profile similar to that of clozapine (2). To our knowledge, there are no published descriptions besides the following one of drooling as a side effect of olanzapine treatment.
Ms. A was a 20-year-old Caucasian woman with a 3-year history of schizophrenia. After an initial 4-week trial of olanzapine, 10 mg/day, with substantial clinical improvement, she was treated solely with olanzapine, 15 mg/day. Her early spontaneous complaints of adverse effects included experiencing morning grogginess and soaking her pillow with saliva during sleep. When we increased her olanzapine dose to 15 mg/day, her morning grogginess and pillow wetting worsened. A physical examination revealed a normal gait and no muscular rigidity.
Among patients treated with antipsychotics, parkinsonism-related drooling is due to throat muscle rigidity and a resultant decrease in saliva swallowing. With clozapine, drooling and pillow wetting presumably result from increased saliva production (hence, the usual descriptors, “hypersalivation” and “sialorrhea”), although the mechanism has not been definitively demonstrated. It is unlikely that Ms. A's drooling was related to parkinsonism because she had no extrapyramidal symptoms.
Two proposed mechanisms for clozapine-induced hypersalivation may be relevant here (35). Increased saliva production results from salivary sympathetic α-adrenergic receptor antagonism or from parasympathetic cholinergic (muscarinic) receptor agonism. Ms. A's sialorrhea may have been a result of olanzapine's potent α-adrenergic antagonism. Alternatively, sialorrhea may stem from stimulation of salivary muscarinic receptors. Both clozapine and olanzapine have high affinity for the five muscarinic receptors (M1–M5), and both are antagonists at M1–M3 and M5, consistent with anticholinergic effects. Clozapine (4, 5) and olanzapine (5) are reported to be agonists or partial agonists at M4 receptors. This explanation is speculative because the importance of M4 receptors in human saliva production is unknown.
While the cause of pillow wetting for Ms. A as well as clozapine-treated patients is not understood, anticholinergic and adrenergic agonist therapies are used for clozapine-induced pillow wetting (1, 3). Although Ms. A declined pharmacological treatment, she welcomed discussion of nonpharmacological management (e.g., covering her pillow with a towel or sleeping on her side propped up with extra pillows). Physicians should monitor patients treated with olanzapine for this potentially troublesome adverse effect.

References

1.
Safferman A, Lieberman JA, Kane JM, Szymanski S, Kinon B: Update on the clinical efficacy and side effects of clozapine. Schizophr Bull 1991; 177:247–261
2.
Moore NA, Calligara DO, Wong DT, Bymaster F, Tye N: The pharmacology of olanzapine and other new antipsychotic agents. Curr Opin Invest Drugs 1993; 2:281–293
3.
Grabowski J: Clonidine treatment of clozapine-induced hypersalivation. J Clin Psychopharmacol 1992; 12:69–70
4.
Zorn SH, Jones SB, Ward KM, Liston DR: Clozapine is a potent and selective muscarinic M4 receptor agonist. Eur J Pharmacol 1994; 269:R1–2
5.
Zeng XP, Le F, Richelson E: Muscarinic m4 receptor activation by some atypical antipsychotic drugs. Eur J Pharmacol 1997; 321:349–354

Information & Authors

Information

Published In

Go to American Journal of Psychiatry
Go to American Journal of Psychiatry
American Journal of Psychiatry
Pages: 993a - 994
PubMed: 9659875

History

Published online: 1 July 1998
Published in print: July 1998

Authors

Affiliations

Diana O. Perkins, M.D., M.P.H.
Robert K. Mcclure, M.D.
Chapel Hill, N.C.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

There are no citations for this item

View Options

View options

PDF/ePub

View PDF/ePub

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - American Journal of Psychiatry

PPV Articles - American Journal of Psychiatry

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share